CN1177829C - 取代磺酰基氨基氰、其制备方法及其作为药物的应用 - Google Patents

取代磺酰基氨基氰、其制备方法及其作为药物的应用 Download PDF

Info

Publication number
CN1177829C
CN1177829C CNB998073148A CN99807314A CN1177829C CN 1177829 C CN1177829 C CN 1177829C CN B998073148 A CNB998073148 A CN B998073148A CN 99807314 A CN99807314 A CN 99807314A CN 1177829 C CN1177829 C CN 1177829C
Authority
CN
China
Prior art keywords
carbon atoms
alkyl
hydrogen
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998073148A
Other languages
English (en)
Chinese (zh)
Other versions
CN1305463A (zh
Inventor
A����ά
A·维切特
H·J·兰
S·佩特里
�������ֿ�
J－R·斯切沃克
H-W·克里曼
S·费博
�������ɭ
H－W·詹森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1305463A publication Critical patent/CN1305463A/zh
Application granted granted Critical
Publication of CN1177829C publication Critical patent/CN1177829C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CNB998073148A 1998-05-06 1999-04-30 取代磺酰基氨基氰、其制备方法及其作为药物的应用 Expired - Fee Related CN1177829C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820064A DE19820064A1 (de) 1998-05-06 1998-05-06 Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19820064.1 1998-05-06

Publications (2)

Publication Number Publication Date
CN1305463A CN1305463A (zh) 2001-07-25
CN1177829C true CN1177829C (zh) 2004-12-01

Family

ID=7866747

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998073148A Expired - Fee Related CN1177829C (zh) 1998-05-06 1999-04-30 取代磺酰基氨基氰、其制备方法及其作为药物的应用

Country Status (26)

Country Link
US (1) US6573288B1 (enExample)
EP (1) EP1076651B1 (enExample)
JP (1) JP4546644B2 (enExample)
KR (1) KR20010043304A (enExample)
CN (1) CN1177829C (enExample)
AR (1) AR016255A1 (enExample)
AT (1) ATE293606T1 (enExample)
AU (1) AU756844B2 (enExample)
BR (1) BR9911009A (enExample)
CA (1) CA2331863A1 (enExample)
DE (3) DE19820064A1 (enExample)
DK (1) DK1076651T3 (enExample)
ES (1) ES2241326T3 (enExample)
HR (1) HRP20000746A2 (enExample)
HU (1) HU225377B1 (enExample)
ID (1) ID28020A (enExample)
IL (1) IL139264A (enExample)
NO (1) NO317886B1 (enExample)
NZ (1) NZ507964A (enExample)
PL (1) PL344041A1 (enExample)
PT (1) PT1076651E (enExample)
RU (1) RU2221789C2 (enExample)
SK (1) SK16582000A3 (enExample)
TR (1) TR200003248T2 (enExample)
WO (1) WO1999057102A1 (enExample)
ZA (1) ZA200006166B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
ITTO20060575A1 (it) * 2006-08-02 2008-02-03 Univ Pisa Inibitori di zinco proteinasi tioaril sostituiti e loro usi
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
IL98319A (en) * 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
TW215434B (enExample) * 1992-03-07 1993-11-01 Hoechst Ag
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19804251A1 (de) 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
US6573288B1 (en) 2003-06-03
EP1076651B1 (de) 2005-04-20
KR20010043304A (ko) 2001-05-25
TR200003248T2 (tr) 2001-03-21
WO1999057102A1 (de) 1999-11-11
HUP0102459A3 (en) 2002-12-28
JP2002513785A (ja) 2002-05-14
NZ507964A (en) 2003-06-30
DE19980787D2 (de) 2001-03-22
JP4546644B2 (ja) 2010-09-15
ZA200006166B (en) 2001-09-26
ES2241326T3 (es) 2005-10-16
AR016255A1 (es) 2001-06-20
ATE293606T1 (de) 2005-05-15
IL139264A0 (en) 2001-11-25
CN1305463A (zh) 2001-07-25
NO317886B1 (no) 2004-12-27
DE19820064A1 (de) 1999-11-11
AU5947999A (en) 1999-11-23
AU756844B2 (en) 2003-01-23
IL139264A (en) 2004-07-25
PL344041A1 (en) 2001-09-24
ID28020A (id) 2001-05-03
HUP0102459A2 (hu) 2002-03-28
BR9911009A (pt) 2001-02-13
PT1076651E (pt) 2005-08-31
EP1076651A1 (de) 2001-02-21
NO20005549L (no) 2001-01-05
SK16582000A3 (sk) 2001-06-11
HU225377B1 (en) 2006-10-28
DE59911949D1 (de) 2005-05-25
HK1038008A1 (en) 2002-03-01
HRP20000746A2 (en) 2001-06-30
RU2221789C2 (ru) 2004-01-20
CA2331863A1 (en) 1999-11-11
NO20005549D0 (no) 2000-11-03
DK1076651T3 (da) 2005-08-15

Similar Documents

Publication Publication Date Title
CN1176911C (zh) 联苯磺酰基取代的五元杂环、其制备方法、其药用和组合物
CN1158279C (zh) 作为血管紧张肽(1-7)受体兴奋剂的1-(p-噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂
CN1087900A (zh) 苯甲酰胍、其制备方法和作为药物及含有它们的药剂的用途
CN1166169A (zh) 用作毒蕈碱性受体别构效应物的杂环化合物
CN1390196A (zh) 具有药理活性的新的二羧酸衍生物
CN1462268A (zh) 取代的肉桂酸胍化物、其制备方法、其作为药物的应用、以及含有这些化合物的药物
CN1221524C (zh) 治疗用的二苯基醚化合物
CN1210257C (zh) 取代的芳香环化合物及其制备方法和用途
CN1035817C (zh) 三唑基取代的叔胺化合物及其盐的制备方法
CN1798737A (zh) 取代的4－苯基四氢异喹啉、其制备方法、其作为药物的用途和含有这类化合物的药物
CN1087285C (zh) 碱性基取代的苯甲酰胍，其制备方法，其作为药物或诊断试剂的用途，以及含有它们的药物
CN1211370C (zh) 具有联苯基磺酰基取代基的咪唑衍生物、其制备方法及其作为药物或诊断剂的应用
HK1049655A1 (en) Substituted norbornylamino derivatives, production and use thereof and medicaments containing them
CN1177829C (zh) 取代磺酰基氨基氰、其制备方法及其作为药物的应用
CN1055920C (zh) 烷基苯甲酰基胍衍生物
CN1177827C (zh) 联苯基磺酰基取代的咪唑类衍生物、其制备方法、其作为药物或诊断剂的应用和含有它们的药物
CN1289321A (zh) 联苯磺酰氨腈、其制备方法和作为药物的用途
CN1171785A (zh) 嘧啶衍生物
CN1047860A (zh) 丁烯酸衍生物
HK1038008B (en) Substituted sulphonyl cyanamides, method for producing same and their use as medicament
CN1264836C (zh) 苯并噁噻哌衍生物及其在制备药物中的用途
CN1882562A (zh) 苯并呋喃和苯并噻吩类化合物
HK1034706B (en) Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament
HK1038743B (en) Imidazole derivatives with biphenylsulfonyl substitution, method for preparing them and their use as a drug or diagnostic agent
HK1009814B (en) Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1038008

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: SANOFI- AVENTIS GERMAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Frankfurt, Germany

Patentee after: Hoechst Marion Roussel de GmbH

Address before: Frankfurt, Germany

Patentee before: Awentis Medicines Deutschland GmbH

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee